Format

Send to

Choose Destination
Anticancer Res. 2017 Jan;37(1):143-148.

Potential Prognostic Molecular Signatures in a Preclinical Model of Melanoma.

Author information

1
Cancer Immunology and Immunotherapy Center, Saint Savvas Cancer Hospital, Athens, Greece.
2
Cancer Immunology and Immunotherapy Center, Saint Savvas Cancer Hospital, Athens, Greece mahaira@ciic.gr.

Abstract

Numerous studies have revealed a variety of pathways involved in the development of melanoma, however, the molecular and genetic divergence of underlying mechanisms remain vague. In a mouse model, we studied the expression pattern of insulin-like growth factor 2 mRNA-binding protein 1 (Igf2bp1) and target genes microphthalmia-associated transcription factor (Mitf), v-myc avian myelocytomatosis viral oncogene homolog (Myc), B-cell lymphoma 2 (Bcl2), prothymosin alpha (Ptma) and melan-A (Mlana) in relation to tumor-growth characteristics. The in vivo expression of the aforementioned genes was assessed by quantitative Real Time-Polymerase Chain Reaction (RT-PCR) in tumors established by B16-F1-derived clones. Gene expression was correlated with tumor growth characteristics. Simultaneous expression of elevated levels of Myc, Igf2bp1, Ptma and Mitf characterizes tumors with a more aggressive phenotype. Our findings introduce a tumor-specific molecular signature possibly associated with melanoma heterogeneity. The concomitant overexpression of key molecules such as IGF2BP1, PTMA, MYC and MITF could serve as prognostic or predictive marker.

KEYWORDS:

Igf2bp1; Melanoma; Ptma; molecular signatures; β-catenin/Wnt pathway

PMID:
28011484
DOI:
10.21873/anticanres.11299
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center